Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyColorado Rocky Mountain Risk Tests Update | OpenPa…
    Ask Trek AI about this page
    ModifiedColorado Rocky Mountain Health PlansPolicy SRST2026T0389GG

    Cardiovascular Disease Risk Tests

    Customize your policy alerts

    Sign up for Colorado Rocky Mountain Health Plans Policy SRST2026T0389GG alerts

    Get alerted when Policy SRST2026T0389GG changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy addresses cardiovascular disease risk assessment tests, including arterial compliance testing, carotid intima-media thickness measurement, advanced lipoprotein analysis, Lp-PLA2 testing, and multiprotein biomarker tests. The identified tests are considered unproven and not medically necessary because evidence is insufficient to establish clinical efficacy or improved outcomes.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyCardiovascular Disease Risk Tests
    Policy CodePolicy SRST2026T0389GG
    Change TypeModified
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionClaims for the identified cardiovascular risk tests are at risk of denial because the services are unproven and not medically necessary.
    SourceLink
    POLICY UPDATE CHANGES

    The coverage rationale was updated with a revised list of unproven and not medically necessary indications.

    CPT code 83695 was removed from the applicable codes.

    The supporting information sections were updated to reflect current information.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    13Applicable procedure and laboratory codes
    1Applicable code removed
    1Prior policy version archived
    11/01/2026Effective date

    Unproven and Not Medically Necessary Services

    Unproven and not medically necessary cardiovascular risk tests

    The following services are unproven and not medically necessary due to insufficient evidence of efficacy:

    Any of the following services

    • Arterial compliance testing using waveform analysis as a method to determine cardiovascular disease risk.
    • Carotid intima-media thickness measurement as an effective screening tool for management of cardiovascular disease.
    • Subfractions or particle-size advanced lipoprotein analysis as a method to determine cardiovascular disease risk.
    • Lipoprotein-associated phospholipase A2 (Lp-PLA2) enzyme testing as a method to determine cardiovascular disease or ischemic stroke risk.
    • Multiprotein diagnostic biomarker analysis, including any of the following: protein biomarker analysis by aptamer-based microarray and algorithm; cholesterol efflux capacity with liquid chromatography–tandem mass spectrometry and quantitative measurement of five HDL-bound apolipoproteins (A1, C1, C2, C3, and C4), with algorithmically reported risk score; three-protein analysis of high-sensitivity troponin, adiponectin, and kidney injury molecule-1 (KIM-1), with algorithmically reported risk score; four-protein analysis of NT-proBNP, osteopontin, tissue inhibitor of metalloproteinase-1 (TIMP-1), and KIM-1, with algorithmically reported risk score; or seven-protein analysis of IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, and MCP-3, with algorithmically reported risk score.

    Arterial compliance testing using waveform analysis is unproven and not medically necessary as a method to determine cardiovascular disease risk.

    Carotid intima-media thickness (CIMT) measurement is unproven and not medically necessary as an effective screening tool for the management of cardiovascular disease.

    Advanced lipoprotein subfraction or particle-size analysis is unproven and not medically necessary as a method to determine cardiovascular disease risk.

    Lipoprotein-associated phospholipase A2 (Lp-PLA2) enzyme testing is unproven and not medically necessary as a method to determine cardiovascular disease or ischemic stroke risk.

    The listed multiprotein diagnostic biomarker analyses are unproven and not medically necessary because evidence of efficacy is insufficient. These include aptamer-based microarray and algorithm testing; cholesterol efflux capacity with quantitative measurement of five HDL-bound apolipoproteins; three-protein, four-protein, and seven-protein algorithmic risk analyses.

    Applicable Codes and Risk-Enhancing Thresholds

    Applicable Codesmixed
    0019MCardiovascular disease, plasma, analysis of protein biomarkers by aptamer-based microarray and algorithm reported as 4-year likelihood of coronary event in high-risk populations.
    0052ULipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation.
    0308UCardiology (coronary artery disease [CAD]), analysis of 3 proteins (high sensitivity [hs] troponin, adiponectin, and kidney injury molecule-1 [KIM-1]) with 3 clinical parameters (age, sex, history of cardiac intervention), plasma, algorithm reported as a risk score for obstructive CAD.
    0309UCardiology (cardiovascular disease), analysis of 4 proteins (NT-proBNP, osteopontin, tissue inhibitor of metalloproteinase-1 [TIMP-1], and kidney injury molecule-1 [KIM-1]), plasma, algorithm.
    0377UCardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by nuclear magnetic resonance (NMR) spectrometry with report of a lipoprotein profile (including 23 variables).
    0415UCardiovascular disease (acute coronary syndrome [ACS]), IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, and MCP-3 by immunoassay combined with age, sex, family history, and personal history of diabetes, blood, algorithm reported as a 5-year risk score for ACS.
    0541UCardiovascular disease (HDL reverse cholesterol transport), cholesterol efflux capacity, LC-MS/MS, quantitative measurement of 5 distinct HDL-bound apolipoproteins (apolipoproteins A1, C1, C2, C3, and C4), serum, algorithm reported as prediction of coronary artery disease (pCAD) score.
    1104TNoninvasive cardiopulmonary assessment, including quantitative parameters, respectively predictive of significant epicardial coronary artery disease, pulmonary hypertension, and/or elevated pulmonary capillary wedge pressure, derived by augmentative algorithmic analysis of orthogonal voltage gradient and photoplethysmography signals, with automated report.
    83698Lipoprotein-associated phospholipase A2 (Lp-PLA2).
    83701Lipoprotein, blood; high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed (e.g., electrophoresis, ultracentrifugation).
    1–10 of 13
    1/2
    Removed Applicable CodeCPT
    83695
    Persistent primary hypertriglyceridemia
    Risk-enhancing factorPersistently elevated primary hypertriglyceridemia is identified as an ASCVD risk-enhancing factor.
    ThresholdAt least 175 mg/dL.
    Collection conditionThe threshold applies to a nonfasting measurement.
    High-sensitivity C-reactive protein
    Risk-enhancing factorElevated high-sensitivity C-reactive protein is identified as an ASCVD risk-enhancing factor when measured.
    ThresholdAt least 2.0 mg/L.

    Claims and Billing Guidance

    Denial Risk

    Unproven Cardiovascular Risk Testing

    Do not bill these cardiovascular risk tests as medically necessary. Claims involving the listed tests should be denied as unproven because insufficient evidence supports their efficacy.

    • Arterial compliance testing using waveform analysis to determine cardiovascular disease risk
    • Carotid intima-media thickness measurement as a screening tool for managing cardiovascular disease
    • Advanced lipoprotein analysis of subfractions or particle size to determine cardiovascular disease risk
    • Lipoprotein-associated phospholipase A2 (Lp-PLA2) enzyme testing to determine cardiovascular disease or ischemic stroke risk
    • Multiprotein diagnostic biomarker testing, including: protein biomarkers analyzed by aptamer-based microarray and algorithm; HDL reverse cholesterol transport, cholesterol efflux capacity, liquid chromatography–tandem mass spectrometry, and quantitative measurement of five HDL-bound apolipoproteins (A1, C1, C2, C3, and C4) with an algorithm and reported risk score; three-protein panels of high-sensitivity troponin, adiponectin, and kidney injury molecule-1 (KIM-1) with an algorithm and reported risk score; four-protein panels of NT-proBNP, osteopontin, tissue inhibitor of metalloproteinase-1 (TIMP-1), and KIM-1 with an algorithm and reported risk score; and seven-protein panels of IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, and MCP-3 with an algorithm and reported risk score

    Policy Scope and Clinical Context

    This policy evaluates tests proposed to identify or stratify cardiovascular disease risk before symptoms or irreversible vascular damage occur. The tests addressed include arterial compliance testing, carotid intima-media thickness measurement, advanced lipoprotein analysis, Lp-PLA2 testing, and multiprotein biomarker analyses. The evidence is insufficient to demonstrate that these tests change clinical management or improve outcomes.

    Clinical Test Definitions

    Carotid intima-media thickness (CIMT)
    Test typeA noninvasive ultrasound-based test.
    MeasurementComputer software measures the thickness of the carotid artery intima-media layers.
    Anatomic siteThe test captures images of the carotid artery.
    Lipoprotein-associated phospholipase A2 (Lp-PLA2)
    Biomarker typeLp-PLA2 is a vascular inflammatory enzyme.
    Investigated useIt has been investigated as a surrogate biomarker of increased coronary heart disease and stroke risk.
    Risk-assessment role

    Services Not Covered Under This Policy

    The following services are not covered because they are considered unproven and not medically necessary due to insufficient evidence of efficacy: arterial compliance testing using waveform analysis for cardiovascular disease risk; carotid intima-media thickness measurement for screening or management of cardiovascular disease; advanced lipoprotein subfraction or particle-size analysis; Lp-PLA2 enzyme testing for cardiovascular disease or ischemic stroke risk; and the listed multiprotein diagnostic biomarker analyses, including aptamer-based, HDL-bound apolipoprotein, three-protein, four-protein, and seven-protein algorithmic risk tests.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyCardiovascular Disease Risk Tests
    Policy CodePolicy SRST2026T0389GG
    Change TypeModified
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionClaims for the identified cardiovascular risk tests are at risk of denial because the services are unproven and not medically necessary.
    SourceLink
    On This Page
    Unproven and Not Medically Necessary ServicesApplicable Codes and Risk-Enhancing ThresholdsClaims and Billing GuidancePolicy Scope and Clinical ContextClinical Test DefinitionsServices Not Covered Under This Policy
    Clinical use
    The measurement may be considered among lipids and biomarkers associated with increased ASCVD risk.
    Apolipoprotein B
    Risk-enhancing factorAn elevated apolipoprotein B level constitutes an ASCVD risk-enhancing factor.
    ThresholdAt least 130 mg/dL.
    Relative indication for measurementMeasurement is relatively indicated when triglycerides are at least 200 mg/dL.
    Ankle-brachial index
    Risk-enhancing factorAn ankle-brachial index below the specified threshold is identified as an ASCVD risk-enhancing factor.
    ThresholdBelow 0.9.
    Guideline contextThe threshold is listed among ACC/AHA risk-enhancing factors for individual clinical risk discussion.
    B-type natriuretic peptide
    BiomarkerB-type natriuretic peptide is a natriuretic peptide used in cardiovascular risk assessment.
    Abnormal thresholdAt least 50 pg/mL.
    Clinical contextFor asymptomatic adults with diabetes, abnormal values should be evaluated using clinical judgment because comorbidities can affect natriuretic peptide levels.
    N-terminal pro-B-type natriuretic peptide
    BiomarkerN-terminal pro-B-type natriuretic peptide is a natriuretic peptide used in cardiovascular risk assessment.
    Abnormal thresholdAt least 125 pg/mL.
    Clinical contextFor asymptomatic adults with diabetes, abnormal values should be evaluated using clinical judgment because comorbidities can affect natriuretic peptide levels.
    Apolipoprotein B goals
    Increased ASCVD riskOptimal apolipoprotein B goal is less than 90 mg/dL.
    Established ASCVD or diabetes with additional risk factor(s)Optimal apolipoprotein B goal is less than 80 mg/dL.
    Extreme riskOptimal apolipoprotein B goal is less than 70 mg/dL.
    It has been used as an adjunct to conventional risk assessment in healthy or asymptomatic adults.
    Arterial compliance testing
    PurposeTesting is intended to assess arterial elasticity or stiffness.
    MethodThe assessment includes waveform-based methods.
    Proposed useWaveform-based methods have been used to estimate cardiovascular disease risk.
    Multiprotein diagnostic test
    Test typeA multiprotein diagnostic or risk test.
    Analytic approachArtificial intelligence interrogates well-characterized clinical datasets.
    Reported resultThe analysis produces a novel, algorithmically scored assessment of heart disease or cardiovascular event risk.
    Carotid intima-media thickness (CIMT)
    Clinical meaningCIMT is a subclinical marker of atherosclerosis.
    Measurement siteIt is measured in the carotid artery.
    Measurement methodIt is measured using noninvasive ultrasound images and computer software analysis of the carotid artery.
    Lipoprotein-associated phospholipase A2 (Lp-PLA2)
    Biomarker typeLp-PLA2 is an emerging vascular inflammatory biomarker.
    Conditions assessedIt is evaluated for cardiovascular and stroke risk.
    Combination useIt may be evaluated alone or with traditional biomarkers for risk assessment.
    Cholesterol efflux capacity (CEC)
    MeasurementCholesterol efflux capacity measures the capacity of HDL to perform reverse cholesterol transport.
    Cellular processThe measurement assesses HDL-mediated removal of cholesterol from macrophage cells.
    Clinical research contextCEC has been studied in relation to coronary artery disease and cardiovascular mortality.
    Coronary artery calcium (CAC) score
    Assessment typeCoronary artery calcium scoring is an imaging-based assessment.
    Clinical findingIt is used to identify subclinical atherosclerosis.
    Risk assessmentIt is used to assess future cardiovascular disease risk.